|
|
1055 Westlakes Dr. Suite 300
Berwyn, PA 19312 USA
phone:610-727-3913
fax:
|
|
| Symbol |
Private |
| Founded |
2008 |
| Employees |
5 |
|
|
| www.qrpharma.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| QR Pharma is developing two clinical stage compounds with novel mechanisms of action to treat Alzheimer's disease (AD) |
|
| Management |
| Maria L. Maccecchini, PhD, President & CEO;
John E. Bennett, VP Operations;
Eugene Cooper, PhD, VP Formulation;
Eve Damiano, PhD, VP Regulatory; |
| |
|
|
| |
|
| Keywords |
| Alzheimer's disease (AD), Down syndrome (DS), Parkinson's disease (PD), disease modifying drugs (DMD) |
|
|
|
| Description |
|
QR Pharma, Inc is a specialty pharmaceutical company founded to develop novel drugs for the treatment of Alzheimer's Disease (AD). The company has two compounds in clinical development. The lead compound, Posiphen, has the potential to be disease modifying and stop the progression of the disease. The compound has been used in over 110 people and was shown to safe. In a mechanism of action study, 10 days of treatment with Posiphen results in 40% inhibition of amyloid precursor protein (APP) in cerebral spinal fluid of mildly cognitive impaired (MCI) patients, confirming its mechanism of action in humans. We also see that lower APP levels lead to inhibition of tau, phospho tau and inflammation and normalize brain chemistry back to what is seen in healthy, normal volunteers. The second compound, BNC, inhibits butyrylcholinesterase and has symptomatic efficacy. We have an active IND and are ready to start phase I. Due to their interesting mechanisms of action, we are targeting Posiphen for MCI and early AD and BNC for moderate to late AD. |
|
| Products / Services |
Both compounds, Posiphen and Bisnorcymserine (BNC) inhibit amyloid formation and may prevent the progression of Alzheimer's Disease. However, their distinct and different characteristics makes Posiphen better suited for mild cognitive impairment (MCI) and early AD and BNC for late and advanced AD.
|
|
| Technology / Differentiation |
| Posiphen and Bisnorcymserine (BNC) work by two novel, different, and independent mechanisms of action. Posiphen inhibits amyloid and tangle formation and may prevent the progression of the disease. Its distinct and different mechanism of action makes Posiphen better suited for mild cognitive impairment (MCI) and early AD. BNC inhibits butyrylcholinesterase, whose levels are increased in the aging and AD brain. Therefore, BNC is targeted to advanced AD.
Alzheimer's disease affects more than 26 million people worldwide. This number is expected to grow to more than 110 million in 2050. Its economic burden and impact on patient wellness and quality of life for both patients and their caregivers is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit trade offs. Therefore, it is imperative to bring drugs to market that stop the progression of the disease. |
|
| Market / Customers |
Alzheimer's disease affects more than 26 million people worldwide. This number is expected to grow to more than 106 million in 2050. Its economic burden and impact on patient wellness and quality of life for both patients and their caregivers is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit trade offs. Therefore, it is imperative to bring drugs to market that stop the progression of the disease.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members